United States · Investor

Apothecary Capital

Last cheque observed Jun 2009. Silence since then is not evidence of inactivity: our sources miss unannounced rounds.

QuietVC firm

Series CSeries DSeries FLife SciencePharmaceutical

Cheques on record
0%of best year0cheques in 12 months, 5 on record
Since the last cheque6342days00hrs00min00sec
Median round$60MRounds led0 of 5Exits3 from the portfolioMostly inUnited States, 100%
Pitch Apothecary Capital

Apothecary Capital highlights

  1. 01

    5 rounds on record

  2. 02

    Mostly Series C and Series D: 80% of its rounds

  3. 03

    3 exits from the portfolio

What they do

Type
VC firm (from a list, unverified)
Cheque size
Not stated
Sectors
Life SciencePharmaceutical
Based in
United States
Cold pitches
Not stated

The record

Every round we can evidence, newest first5 appearances

  1. 2009

    1 round

  2. Jun
    Portola PharmaceuticalsSeries C · US$60MWith 17 others
  3. 2008

    1 round

  4. May
    Kythera BiopharmaceuticalsSeries C · US$30MWith 7 others
  5. 2007

    2 rounds

  6. Dec
    Cogentus PharmaceuticalsSeries C · US · deals.venturebeat.com$63MWith 3 others
  7. Jan
    Calypso MedicalSeries D · US$42MWith 7 others
  8. 2005

    1 round

  9. Feb
    FibroGenSeries F · US · fibrogen.com$100MWith 14 others

An announcement gives the size of the round, not the size of this investor's cheque: the only rounds that imply a cheque are those where they were the sole named investor.

Exits from the portfolio

Companies it backed that were later bought or listed3 in all

Kythera BiopharmaceuticalsBought by Allergan$2.1BJun 2015
Portola PharmaceuticalsListed$100MMay 2013
Calypso MedicalBought by Varian Medical SystemsUndisclosedSept 2011

An exit counts when it came after the firm's first round in the company. From historical deal records.

Who they invest alongside

The investors most often in the same rounds as Apothecary Capital. A count of rooms they were both in, not a relationship either has claimed.

Prospect Venture PartnersVC firm3rounds togetherAdage Capital ManagementAsset manager2rounds togetherBrookside CapitalHedge fund2rounds togetherFrazier Healthcare PartnersPrivate equity2rounds togetherGoldman SachsPrivate equity2rounds togetherJanus Capital GroupGrowth equity2rounds togetherMerlin BiomedGrowth equity2rounds togetherT. Rowe PricePrivate equity2rounds togetherVersant VenturesVC firm2rounds together

Quick answers about Apothecary Capital

What does Apothecary Capital invest in?

Apothecary Capital invests most often at Series C and Series D (80% of the rounds on record), in sectors such as Life Science and Pharmaceutical.

How active is Apothecary Capital?

5 investments on record, 0 of them in the last 12 months. The most recent was in Jun 2009.

How big are Apothecary Capital's cheques?

The median round it joins is $60M.

Does Apothecary Capital lead rounds?

Rarely, if at all: none of its 5 investments on record names it as the lead.

Where does Apothecary Capital invest?

Most of the companies it backs are in the United States (100%).

Is Apothecary Capital investing now?

No investments in the last 12 months; the latest was in Jun 2009.

Who does Apothecary Capital invest alongside?

Most often Prospect Venture Partners (3 rounds together), Adage Capital Management (2 rounds together) and Brookside Capital (2 rounds together).

What kind of investor is Apothecary Capital?

Apothecary Capital is a VC firm based in United States.

Raising now?

Find the investors who back rounds like yours, and keep every conversation on one fundraising board.

Find similar investorsOpen your CRM

Built from the rounds we watched, its filings and its own website, refreshed every night. How we count · Report a correction · Is this your firm? Claim it